gatherbio.com

What It Is

Gather Bio is a patient engagement platform built around autoimmune disease research, serving people with lupus/SLE, rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and related conditions. It currently recruits patients mainly through a waitlist and contacts them for enrollment once local cohorts become available. Unlike traditional one-off sample donation, the site emphasizes that “patients own and control their data”; when de-identified data is used for research and licensing, patients may share in the value generated.

Core Features and Workflow

The platform’s workflow is fairly clear: join the waitlist, complete quarterly mobile blood draws, and have the data support research with the possibility of compensation. Blood collection is performed at home by a mobile phlebotomist and takes about 15 minutes. If a patient feels a flare may be coming, Gather Bio says it will try to arrange a blood draw within 48 hours, helping researchers observe biological changes before, during, and after a flare. For patient advocacy organizations, the platform provides a partnership channel that can connect members to compensated research opportunities focused on respect and transparency, while claiming not to add operational burden to the organization’s team.

Pricing, Security, and Enterprise Capabilities

The website does not disclose SaaS plans, subscription pricing, enterprise quotes, or payment methods, nor does it explain how patient compensation is calculated. On security and compliance, the text explicitly mentions HIPAA-compliant standards, sharing only after de-identification, IRB oversight, and the ability to withdraw at any time without penalty—important fundamentals in a medical research context. However, from an enterprise software review perspective, there is little information about third-party integrations, team permissions, admin consoles, audit logs, cloud/self-hosted deployment, APIs, or developer support. This suggests that its public pages are more focused on research project recruitment than on presenting a mature B2B SaaS product.

Pros, Cons, and Best Fit

Its strengths lie in a patient-friendly experience: mobile blood draws lower the barrier to participation, while data control, withdrawal rights, and value-sharing help build trust. Its focus on samples collected around disease flares also has meaningful research value. The drawbacks are that service availability depends on local cohorts and mobile phlebotomy coverage, with unclear regional availability; the business model, compliance details, and system capabilities are also only lightly disclosed. It is best suited to patients who want to participate in autoimmune disease research, healthy volunteers, and patient advocacy organizations interested in bringing research opportunities to their members.

Access in China and Alternatives

Access from mainland China, payment support, and local service availability are not specified in the text, so china_access can only be assessed as unknown. If deployed in China, it would likely need to consider cross-border medical data compliance, sample collection qualifications, and local ethics approvals. Alternative directions include domestic platforms for clinical research management, patient follow-up, ePRO/eConsent, and decentralized clinical trials.